0001193125-21-287960.txt : 20210930 0001193125-21-287960.hdr.sgml : 20210930 20210930160543 ACCESSION NUMBER: 0001193125-21-287960 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210929 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210930 DATE AS OF CHANGE: 20210930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lyell Immunopharma, Inc. CENTRAL INDEX KEY: 0001806952 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 833006753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40502 FILM NUMBER: 211295136 BUSINESS ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 695-0677 MAIL ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d237206d8k.htm 8-K 8-K
false 0001806952 0001806952 2021-09-29 2021-09-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 29, 2021

 

 

LYELL IMMUNOPHARMA, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-40502   83-1300510

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

201 Haskins Way

South San Francisco, California

   94080
(Address of Principal Executive Offices)   (Zip Code)

(650) 695-0677

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:

  

Trading

Symbol(s):

  

Name of Exchange

on Which Registered:

Common Stock, par value $0.0001 per share   “LYEL”   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 5.02

Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On September 29, 2021, Dr. Richard Klausner, the Chair of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) informed the Company that (a) he will take a temporary medical leave of absence and is expected to return in early 2022 (the “Leave”) and (b) he will also be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2022. However, Dr. Klausner will remain Chair of the Board. The Board has elected Cathy Friedman, its lead independent director, to serve as the interim Chair of the Board during Dr. Klausner’s absence. We do not anticipate the Leave to have any impact on the Company’s timelines for its investigational new drug (“IND”) applications, research and development progress or corporate objectives, and we continue to expect to submit four INDs to the Food and Drug Administration by the end of 2022. The Board and the Company’s employees wish Dr. Klausner a quick and full recovery and look forward to his return to the role of Chair following the Leave.

On September 30, 2021, Dr. Klausner issued a letter to colleagues and stockholders of the Company related to the Leave. That letter is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit No.

   

Description

99.1    Letter dated September 30, 2021 from Dr. Rick Klausner
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Specific forward-looking statements include, without limitation, statements related to the duration of, and expected timing of Dr. Klausner’s return from, the Leave, the anticipated timing of the Company’s IND submissions and any potential impact of the Leave on the Company. Forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from those predicted or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others, those factors that could affect the Company’s business, operating results and stock price included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2021. Undue reliance should not be placed on the forward-looking statements in this report, which are based on information available to the Company as of the date hereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Lyell Immunopharma, Inc.
Dated: September 30, 2021    
    By:  

/s/ Heather Turner

      Heather Turner
      Chief General Counsel
 EX-99.1 2 d237206dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Dear Colleagues and Stockholders:

I am writing to let you know that I am taking a temporary medical leave of absence from Lyell as a result of a recent health situation. I expect to make a full recovery and to return in early 2022.

I want to personally thank all Lyellites for the incredible work they are doing to advance the ambitious and important mission of Lyell. I’d also like to thank my fellow Board members for their support.

Knowing that the company is led by Liz and a truly outstanding leadership team, and that the team is supported by an amazing group of employees who will continue to advance our important mission - curing solid tumor cancers - enables me to focus fully on my health. I am confident that tremendous progress will be made during my leave, and I can’t wait to catch up upon my return.

My family and I deeply appreciate your good wishes and support. Please know that I will be taking a break from general business communications (something new for me!) but I will stay in touch with Liz. I thank you for respecting my and my family’s privacy during this time.

Rick

EX-101.SCH 3 lyel-20210929.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 lyel-20210929_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 lyel-20210929_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 d237206d8k_htm.xml IDEA: XBRL DOCUMENT 0001806952 2021-09-29 2021-09-29 false 0001806952 8-K 2021-09-29 LYELL IMMUNOPHARMA, INC. DE 001-40502 83-1300510 201 Haskins Way South San Francisco CA 94080 (650) 695-0677 false false false false Common Stock, par value $0.0001 per share LYEL NASDAQ true true XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Sep. 29, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001806952
Document Type 8-K
Document Period End Date Sep. 29, 2021
Entity Registrant Name LYELL IMMUNOPHARMA, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-40502
Entity Tax Identification Number 83-1300510
Entity Address, Address Line One 201 Haskins Way
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 695-0677
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol LYEL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d237206d8k.htm d237206dex991.htm lyel-20210929.xsd lyel-20210929_lab.xml lyel-20210929_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d237206d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d237206d8k.htm" ] }, "labelLink": { "local": [ "lyel-20210929_lab.xml" ] }, "presentationLink": { "local": [ "lyel-20210929_pre.xml" ] }, "schema": { "local": [ "lyel-20210929.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lyel", "nsuri": "http://lyell.com/20210929", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d237206d8k.htm", "contextRef": "duration_2021-09-29_to_2021-09-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d237206d8k.htm", "contextRef": "duration_2021-09-29_to_2021-09-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://lyell.com//20210929/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001193125-21-287960-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-287960-xbrl.zip M4$L#!!0 ( +& /E/5/L)8N!( .]P . 9#(S-S(P-F0X:RYH=&WM M7>MSXKBR_[Y5^S^HV+NGDJH -GE"'J>RA,QP)J\#3,V>^V5+V"+HQEA>R4[" M_>M/MR0;\PJ0D&1F-U,U T:O5O=/K7[(FJ-_/@X"2GHH;.;' MLHSMRE"I"+68Y%[:[C'@X=U8LX=MWI8EGU M(0NRZO@0E#PQ0-)=IUJI9@0H/FMXZ-(M_WYYT?;Z;$"+/%0Q#;VL\R262AJHGY(#& M@!KL:;?H5(J5O5PG1<#$6$QU)_ IJV\5S:%MNI\ MA"#."QKPC/KX&?,X8"<'Q2]'9?,5?ANPF!+LH*/ M-:S.I/W.?9^%YCM4N3*X)R$=8%O&:Z<#%OKP-SX/Z*TEXC%NL1X4)U+S^ ]$ M:]&I%BO5/V*1>RJ<]&B@V%%YK/.IP;A_7/BLZ?@#1ORC$0)'AG484M*@&?KL M\0L;%G(DS:FP(FD.K)T#9Z^Z6YFFKSS!&<0G7E%YQ,!;1J[^& MFN.XH/@@"A X^K>^1%)P41?3]5QZ5'Y:3*4G!8IH:67Q"FKHY*@\/A\[^[$9 MZV]0*J679KZ2W![K09T\++'KF//_0XDT23P&8N[WKSR[C )ALCU3/[ MCT"BPL\>867+^(S&[&1$6]IR5#:BU9]3-RW)ALW&*8]Q)^/FB'OE_ HLPTJ% MC]QZQ59%&O#;L.;!7)@LC)<_<#_NUPY*NSP\S-4-6"\^'%!YR\,B?J\1FL0B M_47RV[[]";N+TLY0:1;[3)?"+AUE7<0BJN4>NR*.Q4#_TA422$]_<:-'HD3 M??*+H_\43O[QB[OG'!Z5HWD#;2\>J/+L@7+=[D G9'H"I >B*2K^_ZSF'F3/ M/3K@P;#6X0.FR!5[("TQH.&A+GLP='=%X!_.$,_7JV:G<4;:G=-.HSV?'.>- MR&DWZE];S4ZST2:G5V>D\7O]\^G5IP:I7U]>-MOMYO75BVBLK(/&;Z?MS\VK M3YWKJRUR5JJ72,79W:E.T)4;=!EDC@-BT8J:BFE5:<7^= MGOV2JW0TF51)S!*8^U:H.K]N7GT:WC)RZL4$BMWJ]LY\.M],LFC1(#DM%@D9DXWTF5&P:)B* M";N'FD3J8N9OUA8KA!MM%C6,M;2J9B#&BSLN@.=7\Z&# 33O^W0X!(I8"%L= MB^#'+MB.E>H6P98?BN0M%$EE9QUPFX\>X^"UV"U7Z,W'5U"R\K9R\9_&Q05I M7EY^O;J^^7S:NCS=(LVK>FF&M_<"#>&L@Q,;C4<*F@ 98-9?.G%"%6E'S$,? MQR<\),U8D7H?_!0F)S7;![;G8/LEC,%(#>T&C'@L"%1$/1W!= KZ.:*^GS[; ML>Q+;GQSD5B\4/ZVTFJ$G M).R/6CNU8]BTZB()8SFL"_]%&R"&/C%$$;-(BGL<%G? ,Q;0!]@,I_<]G,4* M,$@Q/U7_'7AXS@,&9;"O/R.HYQ9WG%UG*J;W0S.D0Q^;-M3E:0X\DSL'VT5W MVW%V7>B-)*,5GWP#YI\UPU<8 6<^KYD M2MF/"W#$W)4M@(KCDL]4W0&?R3>F.3"UJ+(A*5"FP/7\@;L<:[/"ZS;NJ\#;Z!2R.DL0;W#7I(Y MC2\R9RW[;@1,./A?'CW'-3JI[C@'/ZP9NX!_&Y9#& RZD8 M'M& -!Z9E\3\ MGI'K'FQ?3&U^WT[-!HB6H&PWI\0R8XM=,>#]NLH&]FP@$4X66L5 M;Z'7$B1H!!'D> J8ER1#UH*-*Q&3TR@* /2 U/?GY3EL%N!S7ND8L23VT2J* M+<)[&!<.;YE/VK@9D0NJ8IO)^8@4OTXZ=1'.8 /O,^].9_]H!!M[)#D&$+KB MD719(!Y0:EB(PB0'Q2^DQP-<"%P1CF?]?)!F+(CB@R2(:$P+>N!1R$>L!T:&QP=944V%&/D$PN9A*VF M&4+;1 @V Q0I&$U@55+S8P!P\/;2U!@H,6"OS%F1\R K@TWI@'K[M"B6\EA=NS, M1X;8':=D:GZ =NV@O9$,]2P>8M9GTW _E> ZK6YB_X7 "TPI>CFN+-2\[HY? MK&QT-Y>#LJG[ >;7!G-3J83)#T@_#]+;K+BSX2T':5MW,:37[CSDK!QCS3,) M_D TZ[BC7J#6NH<9S#?3/T[ _'5/P#PG.+F$QSUGMGT>LR+B@8%^>)!TE>S) M:Z3U.O@6':Z!!O7ZI!Y0I6IO%25_+A??.2_;D117[[MG9-O# 11MJ,T/@2V( M2=H#HNEN]>Z2@[WG6Y_#>FME&U1M?*/\7C.]S\U@V4UYZ%:Z6N.L'*U'*P[8 MUHZ%=[=%(BK)/0T21O['*>$+CB3"-R'[/]R1/@SP5V"T>7RSNL8L]6>=Y9[D MAQ[1/?R^V;(01^E2?LX1]RD;GD%G:>ZX Z;@%54^_9-\"@18]N22RCL6+TR9 MOH5IVPQ]-,\9Z0Z)IV/DT.,=>>@S?;!N(H#-%0$>@VV/@]Z26RD>XCY:^1$& MM:DB/NOQT!R0-]%"9Y=,OW4S>MEFFVP@"O8/=<0PK0S#@"PB/%J/&1;C*E2Z MQS,\RM=E M2;/W!'BV #(SD7A<'"OC)10^E;XR61I_GN^W MO4$SWR\/R])"J3]V,GK->UKO(_(7I2/_:J^RFYRDS4S^_!-L4#.7!AM,K0S\ M*6=?=1D(!^RKX($.5<&\Y83WCV2V&#CF0M9^J>H_A^F$HL>Q"%C9$O%TUG>] M]Q/\_--4C.^WZ]99HU6L7U]PFI4 G6@5@*.[OST9AC MCY'91V$;DPQ0$:+EAF\9#Y$=E3'"+K"3C"SL8:,[00 -E"!=W*T5( [WSIX4 M X*65R3L?DQ5[OR<9B?().5H.C_L7?<8"A((0(_$;K7YH ^OLRW">CT$)Q[" M ]9GDG2U("LE\ED\L'L46R;15)*F9\D&B,)I@99()Y-MWM:HT[@_).>2,Q\H M!H,%X R,16/79Q':'; 2#60B"_1UY-45H=E;+ MBJU$OC'B"VWU@/'!\31B;"P?+1POSD;2-^>Q=%A_"\4-F/'Z6FP^<#T0D58. M8"_=FN.3:'R9-V( A]W_,Y*#IEK03%L[/$ST# PH-?^2[H#'0&$B"8RN\#=S M2@<,.FQYAO2=^@,>:N-0XZMKSN. /)#)!@LC@6*K6?Q(<:4 '*H_ S.4_)EP M,$JQ@UZB\>,)P)?!:B#$'7+R <= *7"5+BA+,UXPI;6?%O_HX$\FO-(3KS^; M6P76K_:VG2FUETV88V(+& 88CV-T!07!# *CMPE3>M(*(R=]V&50B4\L8,D" M:A5+;H8=5%NV/_0EXYB"J>\;G=#G71!VM5IR32NH4$^D1!S9>Q! NOJ UMA. M/2O^?5#\4K([]"17&G"\\,8<@ZK)<>-4X9+I_O2M3;CZ.]22VJ)' Q)+Z\T MUWL6NP&H_K4G,2QR#=ZN1.DY2:BY0>5G94_7SC^]>HJX6E[$/?3CE"=YE+[Q M/ +F:"7,6/#3*$O/A6/)#*[EBG'[1XUR7*B\\1N$T_O&3+FAZ?!:<#$I!DK, M3:)^97N_XNSY[+%:=4O]&+J[,%:-KZV>.6:6\8;R'N9=YEZ"EJ9SN?IWD:#K M[+RJ .MHL9,;F"'XW2 N:AS(,QI3HE\0WT"I^1CAQ0@Q-[Y34^L\@G<:@_=E MKM/:S"^X!8F:@U=X409?24RTIP8>2&:[8/87/!#T*\Z-,U*\ ,\$GW/VS7P_ M8RW1E?D.+KL=:O*@9V*FHTE9R4!HSJB ,X(C8B;T,[^Z=/IZ"V MT/V@ YTX, [I>'NWL63:*=]1*;TMRGN*?*[?N&);>AXB =^(@\.K[;JM?+T) M;RK-!\# AN!1' ?:&Q[,#R98OQ1UT=;(.3-?1U&%?%^S'&;PQXU_KLQ;*T@& M.GZ1P*NQT:). Q"]7(!B/!I1RE ZDS?W(H FDJL[M462T#-Q0V0_3TP"GW@4TT?0,J'HU2NH MK2,-]SJ"9L^5!T.CO$%,4-GV!$S"X,D@"O!2L.X0&.+UGY WS#=/8'YX'2 ) M8\F[2!L8:H&$TIG9")'NQA9?TI":\&]&P!E77J*! MHRN>AC08*JZ#""./K"Y"WX8,H4[+T@=5K@W10$$Z&I\=Y/IWHN]G ]FMJH9< MI_CO5 ]A@ Q[CV'O!S4#4NHK8M*,_TI"-K[%E\C7T$\P AIPO+J>J+Z6!H;L MN@"< $;QTV7PI&8P$1!SQ2,H"'VX!R&-EX7K'DQ@V"@">D]YH!TSJR+JHYR\ M78!HF1# #!.]4IJ#RJ6XM-'X]\USO>MU$^WFIZO3SM=6H_WJ,<#\':TFK_YG MPN4H.;/4-H>56N,)>3^!5:95F9\'+@X#L,=L@ 4M#--E?1KTTD"MUBNV L(S M":&-[@Z$TQ<2)N;_-6,8,Z,6$R\G[*9!AU7B&$]? +-2CT^=H5X_:;MC(99I M3_:-?)-5SJRO%F]X6<^9^[8]+Z3Z1%1C041W7FYRP44>RWBFN$2?(/D^8;"R$OEM6'O3\58[4[_@ M=->*IE)9E(*7 M-"L6S ROSO!8C\KF_UG3_PO;R7\!4$L#!!0 ( +& /E,85$RF8P, +X' M 1 9#(S-S(P-F1E>#DY,2YH=&V]54UOVT80O0O0?YBJ0-$"E10;;=$H MLH#(%F*A2FPX0MLSR=O]Q MMUK>;M[?K,:CY7Z[WVU6F[^G;]_.+I;S88G]^2F ENN[FR^T_G!]M[M[N)K\ M=;O=;R8K&H\0=,TVLE\M;[9_TN?]E]WF:M+J(E:+WV>_:CLA5>N#O9K47,9) MG^O^'&:4/V@[C:Y9O&GB.SJM,Q>C,\-6Z6RVTXT"=N MZ<$9A4KO=]L/GZXF7A\JE%JN5YNOE0G!Q^0T@K&Y8 M>;IV= M0ZIC'X'O' :@BE4=*PHZ)A6ULS-4X:\-YU% &'5DQ)8)&7# /3+*"3?XYSDF M;TE; G=U1Y=O+B]G].I*;:E5M@?70!=G58W:H,<>X=AZZ%9'G"F=QSX#8.Y! M4%8SM*;"G:A6Q:,2NB1:&1A/NS180 O%4>H9'0+H$>[Z$N#IA^\O M?OGM78&R 7)I,!5=KQ2@F(Y*1+F6UD[Y A*9#'#/H+2GD!K)/7MU8_T! _6- MBH6DQ=R91MF.=(!C"LHZVNFGOEV8RB?0Z5(,Z+J08S"57(!*-W"<,C\/\I]S MR182C4>G=H9\RH)']23'#]ZE1EB#6VO7,;"UE:-60ZL'_H MPK-A6XCBC7<'7)$PH,L8U!>PR5 9:?K[-1"P'8]0?G! A"-U[\AJTX1[]N ]6@OMQA""#46CX0;)[)-S$$2FT4D"06W.S0[TBV[Z4>7= M62G4#11!T?\PC1YT?CQ7F>,EQ4MU>E?Q8LJ>/,#8[-_M?P!02P,$% @ ML8 ^4TK"O'M# P 9@L !$ !L>65L+3(P,C$P.3(Y+GAS9+U674_;,!1] MG[3_<)>G35KB) BF1A3$!DA(P*:.37N;W.2V6'/LS': _OO9SD=#"UV!:4@5 MKN\YU\?WR]T_O"LYW*#23(IQD$1Q "AR63 Q'P>U#JG.&0L.#UZ_VG\3AG!\ M>G8)(5P;4^F,D-O;VZB8,:$EKXWUH*-"]-HG1(4TB=/RBHP0R2F"3$ 2%)LSC.TETXNH 3[T; %2MQ MR)750K'YM8&W^3OPK&,I!'*."SAE@HJ<40Y?.\GOX4SD$1QQ#A-'TU:G1G6# M1=1ZO=-%IO-K+.GK5P V8$)GPKJLRW'@(M$&XFZJ>"35G!1&$;.HD%A0:%&H M6!X,J'_GK7%L)IQ%]\09U5-/ZBPN/G$8)^%.,N#Q!?*>X[YPGR$?]%$Z&B + M9#W0*]*81W-Y0ZSA8=\.Q1Z^21K'.\26A;'!QJ$<)GYM8#CSU%;(\) URNV. M)R2CT8AXZXJDPMR_1^M]ES1&CW8?:HQBT]K@J53E,&1 MMF1+%.8>YC["4#5'*&9W8W'KTZ8]E1_)A5"&G_04 FM*B9FLMVR MFZ[$LZ[.)S@#/]DRJG(E.6Z>?Z12LD)EF'T$EJW2.+A6.!L';A2%W13ZR>DT MLE.H@ZP=<+_YG)E8"O+SI;R.:YAQY'-G!F>WKRGEO6M7(.- V[CS0?/^Y^M6 M"I]Z74O1=NC[M#U^ZR\#U),O[\ZYL@APBV^3LP>>C?[=((;>22'+1:/N6.:U M>Y.Z_T>B.!%6T^+,EI0JO9X F'U@)A;^YS7[G:9 MZOJ7K#9PNS-L]&:K&33VZQ]02P,$% @ L8 ^4]%&VZF.!@ .D< !4 M !L>65L+3(P,C$P.3(Y7VQA8BYX;6S-G-MNVT80AN\#Y!VFZDT+A)(HHP4B MQ EI] M^OCVS8?O' =.SR^NP8%%%*W4>#!X?'SL!_=<* S7D994?1^7 W"<+'XR_0*_ M)^7&\)F%S%,,EIZ*F(1?UCP,QJ/AR!W^/'+[HWR:9)[1@\"+V!CR'< M92V_@POA]^$D#.&S25.Z3\7D POZJ6K(Q;]C\]?,= ]OWP#HTRA4O.^X9TY& M>BXV,QGV4\K8[*4\'L4)[OOW[P?QT7RTXK98+>X._KRZO/,7 M;.DY^O3KE\M/RR@^5O'^2_3C*FW(/8PEABRDL+F<%R]E\9'VY6.9YN(B8"ERM^TT4^C%I+=)ZH&OEA2 M,;\_QX=!P+@A9&@V'+/A#-VTS^_UKJ\3U-2?S%0D/3_:K1J:$X4RVQE;.>Y9 MD@:[;9FX$^GO:'G2SW3TYH&SD$8,?-2OWBIR8L4L_5[BTMI%6@XM![^&L]#: MIN%);YDA9\+YO"J8SY(Z M/>.EH.-@'3(D0$YC=E,-*-L6RAT3R6 M5;NE@/),1#S:3G0QZ847^I*\^8UMJ\)9D-P1I.56L"2H";0E@D3P)A4@+0%Q M#=!%&F/<8NMYG.OW3P'V*?IK,T-3[:$JS[LY'6%L;1SWCS6!=E^'B-5,&(QR M8T#IV\QS6;%72AAOF>08G(G@5+_;J4OEL^2.\;1;P9(@"F M@M3D)B5 UP!3 MA SB%EJWTERY?[KEPV-E.,*A)]P&I3F&O9A,K MIS0?A0KRM).Q4Q#BBI"6!%.3:%3^!U^6R7FY.;I1.NY"/0BBM_SY);Z2]@M%.D4 MY$/6L$)P<\1+A6EYUZ5@MQ8M_:U:L8S""_S0#<9)$&@;*OWGD@OFUAL*JT"G M U%F"0\$-A^$0E':(4CUWV4;8"K!C:!:V;1FPS( +_!"/@ 3O7DCI_@H7H1_ M/OTUP&^Q8T/_*8P,_.>2+6%OR@!*,(5HD:A%2ME\U###_E0W***O/ O MOJI_,\BN\!H&PF[*-@X[D63#8%%M:1222J!+4=[@:<]&V1A4]D+R6)6Q*9E7 M!_O=G*X>JK(UCOO'&CU2M:=#A&_\D]\HT]!*W^?.XU05FZ7 T3SS&-XN4-2\ MO;B?UQ&6A0;0?KP)GG8M(D1C<8C5J6ZPM--O'M4Z35/@^H?D4<3$!)?+M4AO MWZBJS!8D=P1NN14L"6J"<(D@$<=I!=@MT9CE%AO/ UVW>PJH[S#D/H^XF%_I M];CD7EB5:%MF1SB7F,"BB"8@%ZD14?PD#YE^8X3;:CG/;ZV^*>"]E2Z#.3K0%((XDJ-<6_;1![[ M%SII80 NE%HSV7P,+#JO8QB*#=I'8B^><# *M-L:CZ1^;KOW78YP\I+\V=)'8%J;QTM!YL@:A$BXC-5AD2Z,9LM-)H' MLVJWE-?0LXV_T)Y9G2?&[;D=7TNM1K XAN*:NJ]'?5W-*M \,=Y>W];K:\7F MZ3X;/%LR.=<3]*O$QVBA%RDK3]3\%F6!1*>?#I;;PH.AS3\?+)$E(C[]4"TK M!$DE2$L1?3[8H@W+!X2UO1 .PD;_+!&*F[N/R1>1:DZ!);_;$2@VA.5Q!/ 7 M:!*3OX&G,NFWQZBP;\F C?DJ+O([+O66^94OZ2Z>_.(3O><_4$L#!!0 ( M +& /E,W8X[JS@0 +\L 5 ;'EE;"TR,#(Q,#DR.5]P&ULU9I= MC^(V%(;O5]K_X&9O6JDA">QL"QIF19F9"G6^!&Q;]69ED@-8=6QDAP'^?8]# MO"(09F&ZK>*Y ,;Q>_SZ/,9)#KG\N$XY>0:EF11=+VJ$'@$1RX2)6==;:I_J MF#&/Z(R*A'(IH.MM0'L?K]Z^N?S.]\GU[>"!^&2>90O="8+5:M5(IDQHR9<9 MAM2-6*8!\7W;OS_^1'[?#M-)IALTH_-",&LU=F0)J MXI&$9M A41A$@>E(HF8G##O-"]*[)S=Y&$'&+(5=K5QL%)O-,_)]_ /)5==2 M". <-N26"2IB1CD96^:NPBV!VU_S3HZCW0GXSSW)TR+'.UA M_O-M-]\T^5'3;T6-M4Z\*S/D-JM*R*Y$1G+-@,QE2K-I^"1/)N=N8)IUS,Q?1O-&'DW MQ$"?SPF4;1;XC= L77#P2+ SD87"12.RO/<=-I0$L,Y ))#8,&8"WWJJ5UN. MQ6*5<6GJ]ON:0](0-V;R.4B F1%#\\'D)?3#J$#T#IL^]R5N%+V)SA2-LW(& MN%DC4ME&3B? NUZ%*/CVMGJ8@L2DX9;3V:FV]D1E6[OL>BHNA:0JMN'P8PG< MX:HO>@0+JC">'\]Q@[/JJ9)I98J*T62E4:D24%VOV6S@M]TC"\6D0O#8XI&E M1B]R85Q3;H[!%)2"Y&X[[:,N_XGD+;KLX_S4)0/<.VO?X/-J;". MB.L+[8AA"Z_E&#R[SXPQF:T9MO ^. 9ONUL,8<;,=$7V0-.3V55KZXNNVJ\E]Y.3Y/!V0:J%5'F"1YAG MZ,LE;OV;ODS.!/F54'7G^A7[%O//3F*^91P>END$U'E,=W5U![CKU=)J.TEK M3->#!)/!IFQ[^_H:=$>#U)WC4>,%U%;H)-1>DF"J=?&&M]40G0>T,D#=85:: MMB CET'V\>.C&LN5>!7&7;DC$'^+5'7;O!+LWJ2.J/\+[8X__*U.H(C-/=<6Y;O'6-I=IB> GH.O;*FOKS* M/BTAUXHUY@<5_C27XLS;B4-=?4D=>K6T7*O._($N,Q!]F:9+45Q-ZU.1'1'7 ME]L1PQ:>:P6:D>0L9AD3LWL\52MF#)Y&KDI97VQ5;BTSUZHM3PK,\@.\HLH+ M\^:74O4XG9Z^4;X4H;X,7W)M6;I6B]F;TT#K):A_3[0BCC-<*[P7=-^[5I09 M0;PT1J/F9,PR?O+EYJ&NOO0.O5I:KE5>QHJ:Q[I&FW0B3SX-[HGJRVG/J(7D M6FW%+K>;=3RG8@;G_!98K:TOLFJ_EIR;-92;%-0,U^&O2JZR.>[["RK.?,[E M2(CZ'-D4$L! A0#% @ L8 ^4]%&VZF.!@ .D< M !4 ( !Z!D &QY96PM,C R,3 Y,CE?;&%B+GAM;%!+ 0(4 M Q0 ( +& /E,W8X[JS@0 +\L 5 " :D@ !L>65L G+3(P,C$P.3(Y7W!R92YX;6Q02P4& 4 !0! 0 JB4 end